Applied DNA Sciences, Inc. (NASDAQ: APDN) Q1 2025 Earnings Call Transcript February 13, 2025 Applied DNA Sciences, Inc. misses on earnings expectations. Reported EPS is $-0.56 EPS, expectations were $ ...
Q1 2025 Management View The company announced a strategic restructuring to focus on its LineaRx subsidiary, exiting the DNA Tagging and Security Products and Services segment. This move is expected to ...
Applied DNA Sciences Inc (APDN) reports increased revenues and strategic shifts, while addressing financial hurdles and ...
Applied DNA Sciences Inc (NASDAQ:APDN) reported its financial results for the first quarter of fiscal year 2025, showcasing a notable increase in revenue but also highlighting ongoing challenges with ...
Announces Exit of DNA Tagging and Security Products and Services Business Segment - - Workforce Reduction of 20% of Headcount ...
InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...
Of note, JN.1-based monovalent mRNA vaccines (JN.1 MV) were also approved in the EU, UK, and Japan in 2024. Clinical studies of JN.1 MVs have led to robust serum neutralising titers against JN.1 ...
Through the agreement, TriLink’s products will now be more widely available in EMEA, including its CleanCap® cap analogs (co-transcriptional mRNA caps), catalog mRNAs, over 150 modified and unmodified ...
mRNA raw materials (nucleotides and other IVT enzymes including wild-type T7 RNA polymerase), advanced scale-up capabilities, and unrivaled expertise in mRNA, oligonucleotide, and enzyme production.
5′CapQ can offer relative quantification without a standard as a function of in vitro transcription (IVT) or enzymatic capping optimization to maximize yield of intact mRNA or can offer absolute ...
Investigational mRNA vaccines are manufactured for individuals based on the specific molecular features of their tumours. Credit: FatCamera via Getty Images. The UK’s drug regulatory authority has ...